Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Award Winning MÜV™ to Open on the Emerald Coast, Marking its Third Medical Cannabis Dispensary in the Florida Panhandle


Shalimar is the 15th new MÜV location this year, for a total of 26 dispensaries across Florida.

AltMed Florida, one of the fastest growing medical cannabis companies in Florida, continues its statewide expansion with a three-day opening, starting Friday October 2, 2020 at 10 a.m. CDT for its newest MÜV™ Medical Cannabis Dispensary located at 1246 Eglin Parkway in Shalimar.

Eglin Parkway is one of the main arterials in the Shalimar/Fort Walton Beach market. MÜV’s 26th Florida dispensary is located minutes from Eglin Air Force Base, the largest air force base in the free world.

“Our third Panhandle dispensary is in a great location – easily accessible from Destin, Fort Walton Beach, Wright, Niceville and Ocean City,” said John Tipton, CEO of AltMed Florida. “We also know this is a very popular vacation destination. Now when Florida patients visit the area, they can access their medications.”

This MÜV dispensary is an old bank building and includes a MÜV-through (drive-through) which offers expedited checkout for express orders. It’s the fourth MÜV to feature a drive-through.

During the opening, staggered over three-days (Oct.2 – Oct.4) for crowd mitigation, all licensed Florida medical cannabis patients will receive a one-time use only, one per patient, 25 percent off their entire first purchase. Patients are also encouraged to order at muvfl.com for express pickup or delivery to help reduce heavy traffic.

Deemed an essential service during the pandemic, AltMed Florida has been able to expand its workforce to over 600 employees with additional teams coming onboard at each of its 15 new dispensaries this year. With higher demand for products from 26 total dispensaries, AltMed has also generated additional construction employment and staffing with the expansion of its massive cultivation facility in Apollo Beach.

The newest state-of-the-art MÜV dispensary will offer an extensive selection of award-winning products including flower, pre-rolls, a wide range of vaporizer pens, metered dose inhalers, topicals and oral sprays; along with patented encapsulation formulations in its EnCaps™ capsules, tinctures, 72-Hour transdermal patches and transdermal gels. MÜV also has one of the widest selections of concentrates for patients needing macro-dosing options.

Like AltMed Florida’s 25 other locations (Apollo Beach, Bradenton, Bonita Springs, Clearwater, Deerfield Beach, Fort Myers, Gainesville, Jacksonville/San Marco, Jacksonville Beach, Lady Lake, Lakeland, Longwood/Orlando, Lutz, North Port, downtown Orlando, Ormond Beach, Pensacola, Port St. Lucie, Sebastian, Sarasota, St. Petersburg, Tallahassee, Tampa, Wellington, West Palm Beach) the new Shalimar MÜV stands out because it’s designed as a premium experience – think Apple Store, with a modern open-concept design and expert staff with extensive training.

The MÜV brand already has a wide following in other legal medical cannabis markets, including Arizona, where it has won five Best of Arizona medical cannabis awards. MÜV products are sold exclusively in Florida at MÜV dispensaries because, unlike other states, Florida does not allow wholesale of product between license holders – only products that license holders make themselves can be sold in their dispensaries.

For more information about the new ADA-compliant MÜV Medical Cannabis Dispensary in Shalimar, including hours and available MÜV products, visit muvfl.com.

AltMed Florida is on pace to open 40 MÜV Medical Cannabis Dispensaries across the state, all supplied by its state-of-the-art cultivation facility. Visit this link for images of AltMed Florida’s cultivation operations and watch this brief video to see what makes AltMed Florida and its MÜV™ Medical Cannabis Dispensaries stand out.

About Plants of Ruskin, LLC – d.b.a. AltMed Florida, LLC – With a focus on quality and attention to detail, Plants of Ruskin has more than 35 years of experience in providing seedlings to farmers for vegetable and medical product production. Plants of Ruskin founders, the Dickman Family, are 4th generation farmers with a long history of working in conjunction with the University of Florida, including an endowed chair specifically dedicated to plant improvement.

About MÜV™ – The MÜV™ brand of medical cannabis infused products was launched in Arizona in 2016 and quickly gained international attention and recognition. MÜV Dispensary by AltMed Florida was formed a year later through the partnership of AltMed Enterprises and Plants of Ruskin, a multi-generational Florida agricultural leader. Through continual research and development, MÜV has received multiple patents for the award-winning MÜV Products line that provides quality, consistent and reliable medical cannabis products to patients at all 26 locations (one in Arizona muv-az.com, 25 in Florida muvfl.com, and more added each month). Patients are encouraged to place reservations online at muvfl.com for in-store pickup, order for delivery, or visit any one of the 26 MÜV Dispensaries for alternative medical cannabis medicine you can trust.

About AltMed Enterprises – Alternative Medical Enterprises, LLC, headquartered in Sarasota, FL and doing business as AltMed Enterprises, is a fully integrated medical cannabis company that brings compassion, community engagement and pharmaceutical industry precision to the development, production and dispensing of medical cannabinoids.

Forward-Looking Statements -

To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking in nature and merely express our beliefs, expectations or opinions. For example, words such as “may,” “should,” “estimates,” “predicts,” “continues,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” “strategy” and similar expressions are intended to identify forward-looking statements. Such statements are based on current expectations or estimates and involve a number of known and unknown risks and uncertainties that could cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, the following: (i) our ability to implement our business strategy of distributing high quality cannabis products where permissible under applicable law; (ii) availability and cost of additional capital; (iii) our ability to attract, retain and motivate qualified employees and management; (iv) the impact of federal, state or local government regulations; (v) competition in the cannabis industry; (vi) our ability to generate revenues; and (vii) litigation in connection with our business. All forward-looking statements included in this press release and attributable to us or any person acting on our behalf are qualified by this cautionary statement. Forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

Zimmerman & Frachtman Law Firm Now Offering Legal Services for Clients Harmed by Defective Insulin Pumps


Zimmerman & Frachtman Law Firm - Legal Services for Clients Harmed by Defective Medtronic Insulin Pumps

“We are experts in this area of law and can walk you or your loved one through the legal process,” said attorney Joshua Frachtman. “It’s important to remember that there are time limits on when you can file a claim to be compensated for injuries from a Medtronic insulin pump.”

The Zimmerman & Frachtman Law Firm are proud to announce that they will start taking cases for clients concerning the recall of Medtronic insulin pumps deemed defective by the United States Food and Drug Administration.

In its Class I recall notice, the FDA relayed that the Medtronic 630G and 670G insulation pumps “may cause serious injuries or death,” and attributed at least one death to the faulting medical devices in addition to well over 2,000 injuries across 26,000 complaints. Though Medtronic designed the pumps to deliver specific amounts of insulin into bloodstreams, the retainer rings that seal the insulin reservoir have repeatedly broken or shipped defective, compromising the entire device.

The broken rings can lead to two significantly negative outcomes for users of the pumps. For one, diabetics that continue to use the pump are at risk of exceeding their recommended dosage, which may decrease blood sugar to hazardous levels. Specifically, excess insulin can cause irregular heartbeats, vision problems, seizures, and many other harmful side effects. Chief among these is insulin shock, which may lead to a coma or even death.

Conversely, the inability for the pump to deliver consistent appropriate dosage can also result in the user receiving too little insulin, which raises blood sugar to the point it can cause diabetic ketoacidosis. In this case, side effects can consist of headaches, nausea, abdominal pain, and other serious complications. As with excess insulin, shortages can also result in a coma and/or death in serious cases.

“We are experts in this area of law and can walk you or your loved one through the legal process,” said attorney Joshua Frachtman. “It’s important to remember that there are time limits on when you can file a claim to be compensated for injuries from a Medtronic insulin pump.”

Medtronic has posted a Product and Safety notice on their website that provides additional information on the issues and precautions recommended to insulin pump owners. Users exhibiting symptoms should contact their doctor or seek immediate medical attention.

For more information on the defective Medtronic insulin pump, please visit the Zimmerman & Frachtman website.

About Zimmerman & Frachtman

For over 25 years, the team at Zimmerman & Frachtman has been providing personalized attention to each client. They are dedicated to defending the injured and seeking justice on behalf of every client.

Their entire staff believes that the best results are obtained through good and committed hard work. Over the past 25 years, the firm’s trial attorneys have recovered more than $300 million in verdicts and settlements on behalf of their clients. While they are quite proud of their past accomplishments, they remain true to the ideals of compassion, tenacity, consistency, discipline, and respect for others.

For more information, please visit the Zimmerman & Frachtman website or call (954) 509-1900.

Share article on social media or email:

Michael C. Bush, CEO Great Place to Work, to Keynote at 2020 Global Wellness Summit on Why Equitable Workplaces Are Better for Business


The GWS announced that Michael C. Bush, CEO of Great Place to Work® and renowned workplace culture expert, will keynote at its conference November 8–11, 2020, at The Breakers Palm Beach, Florida.

The pandemic has created a major shift in work culture—forcing many businesses to become more flexible when it comes to remote workers, for example. At the same time, there’s been an acceptance of the fact that racial inequality permeates every aspect of our lives.

The Global Wellness Summit (GWS), the foremost gathering of international leaders in the multi-trillion-dollar global wellness economy, today announced that Michael C. Bush, CEO of Great Place to Work® and renowned workplace culture expert, will keynote at its conference November 8–11, 2020, at The Breakers Palm Beach, Florida. The theme of the 2020 GWS is “Resetting the World with Wellness,” and Bush will be one of the experts exploring how innovative and more democratic wellness concepts could transform human life post-COVID-19.

Bush’s presentation, which will include new research conducted during the pandemic with hundreds of the world’s leading CEOs, is entitled, “A Great Place to Work For All,” and is based on his organization’s inclusive leadership model and book by the same name. Bush will outline the importance of wellness and inclusivity in creating positive workplaces and quantify the ROI that these businesses achieve, such as typically outperforming peers in the stock market.

“The pandemic has created a major shift in work culture—forcing many businesses to become more flexible when it comes to remote workers, for example. At the same time, there’s been an acceptance of the fact that racial inequality permeates every aspect of our lives. These two monumental moments have created new challenges and opportunities for business leaders across the globe,” said Susie Ellis, GWS chair and CEO.

Great Place to Work is a global authority on high-trust, high-performance workplace cultures, operating in over 60 countries, providing the benchmarks, framework and expertise needed to create, sustain and recognize outstanding workplace cultures. The company is responsible for popular workplace lists, including “Best Workplaces for Women,” “Best Workplaces for Millennials,” and “Best Companies to Work For.”

Bush’s popular workplace culture book “A Great Place to Work For All” has garnered kudos and recommendations from CEOs of some of the world’s leading companies, including Intuit, Salesforce, Kaiser Permanente, PwC and Marriott International. Said Salesforce CEO Marc Benioff: “The most successful companies have a higher purpose and are built on a foundation of trust, growth, innovation, equality, and making the world a better place for all. “A Great Place to Work For All” shares the essential values that every organization should follow to thrive in the future.”

More about Bush:

Michael C. Bush is a global chief executive with over 25 years of experience leading small and mid-sized organizations through transformational growth. Driven by a love of business and an unwavering commitment to fair and equitable treatment, in 2015, Michael acquired ownership and currently serves as the global CEO of Great Place to Work. Bush set a new mission for the company: to build a better world by helping every organization become a Great Place to Work For All™ by the year 2030.

Bush is also a sought-after speaker and regular contributor to Fortune and has been featured in numerous publications, including Harvard Business Review, Wall Street Journal, Forbes, Inc., ThriveGlobal, Huffington Post, CNBC and TED.

Capacity at the 2020 Summit is limited; delegates are urged to register ASAP. To learn more about the Summit or to register, click here.

About the Global Wellness Summit: The Global Wellness Summit is an invitation-only international gathering that brings together leaders and visionaries to positively shape the future of the $4.5 trillion global wellness economy. Held in a different location each year, Summits have taken place in the US, Switzerland, Turkey, Bali, India, Morocco, Mexico, Austria, Italy and Singapore. The 14th annual Summit will take place at The Breakers Palm Beach, FL, from November 8–11, 2020. The 2021 GWS will be held in Tel Aviv, Israel, November 15–18.

Share article on social media or email:

Sugarlogix Welcomes Paula Hicks as new Chief Technology Officer


Sugarlogix CTO Paula Hicks

Hicks is a proven technical leader with 20 years of broad experience in diverse industries utilizing biotechnology to produce small and large molecules in food & beverages, flavors and fragrances, pest control, and pharmaceuticals.

Sugarlogix, a bioengineering company creating functional oligosaccharides with health benefits, today announced the appointment of Paula Hicks as its new Chief Technology Officer (CTO). In her new role at Sugarlogix, Hicks joins the senior management team and is charged with developing its overall strategy for using technological resources with immediate plans to scale operations and manufacturing.

Hicks is a proven technical leader with 20 years of broad experience in diverse industries utilizing biotechnology to produce small and large molecules in food & beverages, flavors and fragrances, pest control, and pharmaceuticals. Before joining Sugarlogix, Hicks was at Evolva for more than seven years, most recently as the Senior Vice President of Technology in the Commercial Team. While at Evolva, Hicks had vital leadership roles in commercializing products such as stevia, vanillin, and nootkatone.

Before Evolva, Hicks’ experience ranges widely from startups to large corporations. She was one of the early employees and built the R&D strategy at Abunda, a startup later acquired by Evolva. Hicks spent the first nine years of her career at Cargill, Inc., where she was a Principal Scientist in the BioTechnology Development Center. Her passion for developing creative and efficient technologies to take products to commercialization is what led her to Sugarlogix.

“Sugarlogix’s novel technology to utilizing yeast to produce HMOs (human milk oligosaccharides) and the technology’s relative maturity immediately impressed me,” said Hicks. “The impact of delivering yeast-produced HMOs to the infant nutrition market is colossal, and I look forward to participating in this opportunity.”

“We are thrilled to appoint someone of Paula’s caliber as our CTO. Having her on our team prepares us well for Sugarlogix’s next stage of growth in scaling up, commercialization, and expansion of R&D operations,” said Sugarlogix Co-Founder and CEO Chaeyoung Shin.

“Paula is among a very select group of people with a deep track record of developing novel fermentation routes for several highly innovative food ingredients. With this appointment, Sugarlogix continues to strengthen its position as the leading player in yeast-based HMO development,” said Sugarlogix Board Chair, and Former CEO of Evolva, Simon Waddington.

About Sugarlogix

Sugarlogix, whose mission is to create functional sugars with health benefits, is a bioengineering company that makes human milk oligosaccharides (HMOs) for infant nutrition. HMOs are the fiber-equivalents in human breast milk that play crucial prebiotic functions in babies’ guts. Sugarlogix’ novel HMO-producing technologies offer safe and affordable HMOs for babies without access to breast milk.

Founded in 2016 and led by Co-Founder and CEO Chaeyoung Shin, Sugarlogix is headquartered in Oakland and is financially backed by 8VC, Berkeley Catalyst Fund, and SOSV and private investors. For more information, visit http://www.sugarlogix.com or follow us on LinkedIn, Facebook, Twitter, and YouTube.

Share article on social media or email:



321 Insight Announces Resources to Help K-12 Staff Navigate Stress, Trauma


321 Insight, an organization empowering all school staff to meet the needs of today’s students, is releasing a content update with flexible online training options for topics related to distance learning, social-emotional learning (SEL) and COVID-19.

“These resources are meant to help districts navigate new stress and trauma facing students and staff by building capacity through relevant and effective videos and tools,” said Alia Jackson, president of 321 Insight. “Given the impact of the pandemic, social unrest, a contentious election cycle and other events, it’s crucial that educators and staff members alike feel supported and are set up for success.”

Topics covered in the content update include:

  • Educator Wellness During COVID-19
  • Daily Self-regulation Strategies for Staff in Distance Learning
  • Teaching Social Emotional Skills (SEL) Virtually
  • Developing Relationships via Distance Learning
  • Applying Trauma Informed Practices While Maintaining Safety Protocols in Brick and Mortar Schools

“We’ve found 321 Insight’s new content to be very useful – the reaction to the self-care modules has been especially positive,” said Jennifer Lucas, assistant principal at Southwest Cook County Cooperative Association for Special Education. “Having everything online is invaluable, and allows our staff to work through modules individually, as well as in groups where we’re able to utilize the discussion questions 321 Insight provides.”

321 Insight’s online professional development resources are designed by expert practitioners, and offer a flexible solution to educator training. The organization delivers cost-effective, easy-to-implement solutions for training staff and increases their ability to support learners with diverse needs, including the ParaSharp Series for paraeducators and Trauma Informed Series for all school staff.

To learn more about 321 Insight’s flexible training options, please visit https://www.321insight.com/schools/.

About 321 Insight

321 Insight empowers all school staff to meet the needs of today’s students through accessible online content and a proven training model. Created by industry experts and experienced practitioners, the organization equips educators with practical, actionable strategies and guidance to support every learner. 321 Insight offers on-demand digital content that covers topics including trauma-informed practices, behavior management and support, inclusion strategies, setting boundaries, thinking functionally, support strategies for diverse learners and SPED eligibility. To learn more, visit https://www.321insight.com/.

Share article on social media or email:

American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) Launch New ImageGuide Registry Platform


ImageGuide Registry

“We are greatly looking forward to expanding our registry offerings in both the nuclear and echo modalities. ARMUS’s capability in both healthcare and technology provides an ideal combination for ImageGuide to excel,” says Rami Doukky, MD, FASNC, FASE, chair of ASNC’s Registry Committee.

The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) today announced the launch of the new, improved ImageGuide Registry®. ASNC and ASE have selected ARMUS Corporation as the new registry vendor. This partnership will enable the ImageGuide Registry to expand and capitalize on new technology to support its mission of improving patient outcomes in cardiovascular imaging.

The updated registry platform is built using the ARMUS HYBRID Registry Platform, which leverages the most advanced cloud technologies to provide new interfaces, including user-friendly dashboards and data visualizations, available to view in real time on a smartphone, tablet or computer. With over 20 years in the industry, ARMUS provides flexible query and reporting capabilities through its HYBRID Analytics application to support quality and efficiency improvement efforts. Registry participants will be able to view their specific registry data to benchmark their performance on nuclear cardiology and echocardiography measures at both individual physician and overall institution levels.

“We are greatly looking forward to expanding our registry offerings in both the nuclear and echo modalities to our participants and society members. ARMUS’s capability in both healthcare and technology provides an ideal combination for ImageGuide to excel,” says Rami Doukky, MD, FASNC, FASE, chair of ASNC’s Registry Committee.

“Through this partnership with ARMUS and the re-launch of our registry, the mission of ImageGuide will be able to be fully realized through automatic data capture, outcomes connections and potential for image inclusion. ASE looks forward to leveraging this information for the benefit of patient care,” says Sherif Nagueh, MD, FASE, chair of ASE’s Registry Committee.

ARMUS has extensive experience with integrating and acquiring data from over 500 hospitals nationwide and is a certified vendor for several ACC, STS and state clinical registries. This experience will allow more institutions to submit data to the ImageGuide Registry automatically through PACS or reporting software integration.

“ARMUS is very pleased to be working with both ASNC and ASE in the ImageGuide Registry. We look forward to partnering with the societies to develop advanced statistical models for decision support, performance-based reports, interactive dashboards and comparative analytics in cardiovascular procedures,” says Gyula Sziraczky, President & CEO of ARMUS Corporation.

To enroll in the ImageGuide Registry, labs may submit a form on the Contact Page, and ImageGuide Registry staff will reach out with next steps.

#########

About the American Society of Nuclear Cardiology: For over 25 years, ASNC and its more than 4,300 members have been improving cardiovascular outcomes through image-guided patient management. As the only society dedicated solely to nuclear cardiology, ASNC establishes standards for excellence in cardiovascular imaging through the development of clinical guidelines, professional medical education, advocacy and research development. ASNC provides peer-reviewed original articles through its Journal of Nuclear Cardiology and operates the nation’s first noninvasive cardiac imaging registry, ImageGuide Registry®, to benchmark quality and improve patient care. For more information, visit http://www.asnc.org and follow us on @MyASNC and facebook.com/MyASNC.

About ASE: ASE is the Society for Cardiovascular Ultrasound ProfessionalsTM. Over 17,000 physicians, sonographers, nurses, veterinarians, and scientists are members of ASE, making it the largest global organization for cardiovascular ultrasound imaging and as such the leader and advocate, setting practice standards and guidelines for the field. The Society is committed to advancing cardiovascular ultrasound to improve lives. For more information about ASE, visit: ASEcho.org or follow us on @ASE360.

About ARMUS: ARMUS has provided data management and data science services to hundreds of institutions including healthcare providers, payers and premiere medical societies for more than 20 years. Our custom data acquisition and predictive analytic solutions enable healthcare providers to make educated decisions that result in optimal clinical and financial outcomes for individual patients, hospitals and health systems. Our proprietary HYBRID technology platform runs on the most advanced Google Cloud environment, allows us to develop custom data programs at lightning speed and to translate and transfer data from any other complex registry or device into actionable reporting platforms around the world.

Share article on social media or email:



Konan Medical Introduces CellChek20™, the Next Generation Specular Microscope


CellChek 20 from Konan Medical

The new, blazing-fast, one touch specular microscopy exam with Konan Medical’s CellChek 20™

Konan’s CellChek 20 sets a new bar for image quality and size, precision cellular analytics, and one-touch convenience.

Konan Medical (Japan) and Konan Medical USA, Inc., global leaders in innovative diagnostic devices for the ophthalmic industry today announced the launch of the newest endothelial imaging system: CellChek 20.

Specular microscopy from Konan Medical is widely regarded as the Gold Standard for cellular imaging and analytic assessment of the corneal endothelium. CellChek 20 adds a single-button press exam that acquires images of both eyes and the automated analysis with the new, fully-automated Center Method™. CellChek 20 also features larger imaged area, superior image clarity as well as guttata recognition and redaction from cellular calculations.

“CellChek 20 offers a new level of convenience for our customers,” said Konan (Japan) CEO Tetsuji Ikegami. “Even during COVID, the interest has been particularly strong for high-tech, low-touch clinical specular microscopy found in CellChek 20.” Konan Medical USA CEO Charles Stewart added, “CellChek 20 has immediately generated a rebound in sales from customers and distributors. New analytic tools, compact package, and blazing fast, one-button for positioning, alignment, capture and analysis, for both eyes. The best specular product Konan has ever produced.” A demonstration video of CellChek 20 can be seen at https://vimeo.com/461578916 .

Specular microscopy is a diagnostic device for ophthalmology, optometry, and eye banking that assesses the density and morphology of the cornea’s inner-most layer, the endothelium. Considered the “canary in the coal mine”, specular microscopy provides important insight into the health of the cornea, that can be commonly missed with standard examination techniques and is widely used prior to many eye surgeries, FDA clinical trials, routine eye exams and contact lens exams. Konan Medical is a pioneer in specular microscopy devices since 1979 and is mentioned in FDA panel minutes as being the “gold standard”.

CellChek 20 is FDA 510(k) cleared and CE marked.

Originally planned to be introduced at the world’s largest Ophthalmology meeting, the American Academy of Ophthalmology (AAO), Konan has made CellChek 20 available in Japan, Europe, North America and other regions through direct sales and distribution channels.

About Konan Medical, Inc. (Japan).

Headquartered in Hyogo, Japan, Konan started its business in 1947 and has served precision optics, industrial and ophthalmic markets including development of the world’s first disposable camera, with over 1,600 issued patents. Konan has dominated the specular microscopy business segment for over 40 years. Visit Konan at: https://konan.com/en/w/.

About Konan Medical USA, Inc.

Headquartered in Irvine, California, Konan Medical USA Inc. develops specialized diagnostic products for eye care clinicians and eye banks. The company also provides diagnostic equipment and support services to many of the leading ophthalmic manufactures in support of sponsored FDA clinical trials research in the United States and Internationally. A new web presence can be seen at: http://www.KonanMedical.com.

Share article on social media or email:

Amid the Pandemic and Uprising for Racial Justice, Momentum To End the 44-Year-Old Hyde Amendment Is At An All-Time High


Today’s 44th anniversary of the Hyde Amendment comes amid a national uprising for racial justice, allegations of forced sterilization of immigrant women, as well as a global pandemic that has caused hundreds of thousands of deaths and, in the U.S., has fallen hardest upon Black and Brown women. We also face a consequential Supreme Court nomination that will have implications for our rights, including for abortion, for generations. This year, more than ever, the harms of the Hyde Amendment are on full display and demonstrate why it’s time to end this policy once and for all.

“What do police violence, wage gaps, likelihood of contracting COVID-19, and abortion coverage bans all have in common? They’re all rooted in systemic racism that denies the humanity of Black, Indigenous, and people of color and their ability to thrive,” said Destiny Lopez, co-director of All* Above All. “We’re united AF on at least one solution for a better future: lift the Hyde Amendment now.”

The Hyde Amendment, a policy that is rooted in systemic racism, denies people struggling financially, especially women of color, the ability to build their families on their own terms and furthers the harms for those who are already marginalized by our health care system.

“For 44 years too long, the Hyde Amendment has banned abortion coverage – keeping people from getting the critical health care they need,” said Fatima Goss Graves, President and CEO of the National Women’s Law Center. “It is one in a web of abortion restrictions that are part of a system of racist, sexist violence and control. Congress must do better and permanently eliminate Hyde. Our national focus should be on expanding health care options including abortion care – especially during a global pandemic – and rejecting policies that attack Black, Indigenous, Latinx, and Asian American Pacific Islander (AAPI) people.”

Since 1976, the Hyde Amendment, which restricts coverage for abortion for people enrolled in Medicaid and other federal health programs, has put abortion care out of reach, particularly for people struggling to make ends meet, women of color, young people, and immigrants. Studies show that when politicians place restrictions on Medicaid coverage for abortion, they force one in four poor women to carry an unwanted pregnancy to term. Research also shows that denying abortion coverage forces low-income women deeper into poverty, which is especially harmful at a time when women’s unemployment is at an all-time high.

“We hear it every day,” said Parker Dockray, executive director of All-Options. “People’s lives have been upended by the pandemic and economic crisis, and families are struggling to meet their basic needs, from diapers and formula for their children to struggling to pay for their abortion care due to loss of income. We must do away with abortion coverage bans like the Hyde Amendment and ensure everyone has the support they need to make their own decisions with dignity and respect.”

Thanks to the leadership of women of color, elected officials at every level across the country are bold and united in their support to end the Hyde Amendment once and for all. The EACH Woman Act, a groundbreaking bill led by U.S. Senator Tammy Duckworth in the Senate and U.S. Rep. Barbara Lee in the House that would ensure public and private coverage, is up to 207 co-sponsors. Earlier this year, U.S. Representatives Ayanna Pressley, Alexandria Ocasio-Cortez, Barbara Lee, and Jan Schakowsky filed an amendment to strip Hyde from the federal spending bill. Local elected officials in cities like Austin and New York have stepped up for the second consecutive year to dedicate funding within their city budgets to practical support for abortion care.

Voters are united to end the Hyde Amendment – support for Medicaid coverage of abortion remains at an all-time high, with 62% of voters believing that the program should cover abortion. The same poll shows that support for Medicaid coverage of abortion is even higher in battleground states, with 69% of voters supporting coverage.

###

All* Above All unites organizations and individuals, including 130 partner organizations, to build support for lifting bans that deny abortion coverage. Our vision is to restore public insurance coverage so that every woman, however much she makes, can get affordable, safe abortion care when she needs it. Learn more at allaboveall.org and follow our social media at @allaboveall.

Share article on social media or email:

Physician Prescribes a Life in Medicine; Marvin J. Stone, MD, MACP, FRCP writes book to inspire the next generation of doctors


Medical Doctor Prescribes a Future in Medicine

The future IS exciting!

“Martin Stone is a classical triple-threat medical academic: accomplished in biomedical research, expert in his clinical field, and revered teacher. He has written a book of immense value.”

–Jeremiah A. Barondess, MD, William T. Foley Distinguished Professor in Clinical Medicine, Weill-Cornell Medical College

“No other profession is like medicine. The future of medicine is exciting,” says Marvin J. Stone, MD, MACP, FRCP of Dallas, Texas, chief emeritus, hematology and oncology at Baylor University Medical Center at Dallas, a professor of internal medicine at Texas A&M College of Medicine and clinical professor of humanities at the University of Texas at Dallas. Advances in medical science are developing in dizzying speed. Despite the myriad challenges facing students and new doctors, it is reassuring to note that the number of applicants for medical schools in the United States remains high.

With the release of his book “When to Act and When to Refrain: A Lifetime of Learning the Science and Art of Medicine” (Revised and Updated, 2020). Dr. Stone draws from a lifetime of practicing medicine with a passion to inspire and convey to anyone interested in a medical career the excitement and fascination intrinsic to becoming and serving as a physician. He invites students, young doctors, experienced physicians, and lay persons with interest in medical science and health care to an eye-opening look inside his journey through the last half-century in medicine: becoming a physician, acquiring intense training in patient care and research, and teaching at all levels.

A warm and engaging autobiography, Stone says, “Looking back over my career, I’ve had the wonderful opportunity to teach, do research, and care for patients while continuing to learn the science and art of medicine. To see your students excel, to perform an experiment that yields new scientific knowledge, and especially to help some seriously ill patients recover so they can see their children and grandchildren grow up––what more could one ask?”

As we turn towards the future and our goals for 2050, he emphasizes the importance of maintaining core values. He says, “We must always bear in mind the three pillars of medicine: Competence, Caring, and Compassion. Further adding, “These core values in medicine and science are crucial to fulfilling our goals: to cure sometimes, to relieve often, and to comfort always.”

The late Jimmie Holland, Founding Chief of Psychiatry, Memorial Sloan-Kettering Cancer Center was right when she said “that the doctor-patient relationship will continue, although perhaps in an altered fashion.” What will not be altered is the need for physicians to relieve suffering and embrace healing, competence, empathy, and compassion. Dr. Stone concludes by appealing to time-honored ideas and principle and says, “Focusing on these pillars of our profession will help us decide ‘when to act and when to refrain’.”

To learn more visit, marvinjstonemd.com

Books are available through Amazon.com and BarnesandNoble.com

ABOUT THE AUTHOR

Marvin J. Stone received his MD with Honors from the University of Chicago in 1963. After postgraduate training at Barnes Hospital, the National Institutes of Health, and Parkland Memorial Hospital, he joined the faculty of the University of Texas Southwestern Medical School in hematology-oncology. In 1976, he became the first chief of oncology and director of the Baylor Sammons Cancer Center in Dallas, positions he held for 32 years. He taught medical students, residents, and fellows for over 40 years and received teaching awards from each. Dr. Stone is the author of over 250 published articles and book chapters dealing with hematology-oncology and medical history. He is a Master of American College of Physicians and past president of the American Osler Society. Dr. Stone is currently chief emeritus of hematology and oncology at Baylor University Medical Center at Dallas, a professor of internal medicine at Texas A&M College of Medicine, and clinical professor of humanities at the University of Texas at Dallas. He is a fellow of the Royal College of physicians (London) and a member of the board of trustees of Southwestern Medical Foundation.

# # #

Share article on social media or email:

Helixmith Announces Acceptance of Abstracts for 2020 Annual NEALS Meeting


Helixmith, a gene therapy company, announced today that three abstracts have been accepted for poster presentations at the virtual 2020 Annual NEALS Meeting to be held September 30th and October 1st.

Details of the poster presentations are as follows:

Title: Introducing a Drug Development Platform for ALS, DART (Defeating ALS through Restorative Therapeutics)

Poster Number: 89

Presenter: Dr. Sunyoung Kim, CEO, Helixmith

Title: Gene Therapy for ALS: A Phase 1/2 Study of VM202 (Engensis®), a Plasmid DNA Encoding Human Hepatocytes Growth Factor and Plan for Phase 2

Poster Number: 48

Presenter: Dr. John A. Kessler, Professor of Neurology, Pharmacology, and Stem Cell Biology, Northwestern School of Medicine

Title: Intrathecal delivery of recombinant AAV1 encoding human hepatocyte growth factor (HGF) improved motor functions and protects neuromuscular system in two mouse models, nerve crush and SOD1-G93A transgenic

Poster Number: 07

Presenter: Dr. Boram Nho, Research Scientist, Helixmith

Dr. Kim, Dr. Kessler, and Dr. Nho will be available to answer questions on our posters during the live Virtual Poster Session on September 30th from 5:30 pm – 6:30 pm EST. Please visit https://www.neals.org/for-als-researchers/annual-neals-meeting/ for full information including registration.

About Helixmith

Helixmith is a gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals to tackle previously untreated diseases, and is listed on KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), a more advanced pipeline candidate, is a plasmid DNA therapy being studied for diabetic peripheral neuropathy, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis (Phase 2 beginning in late 2020), coronary artery disease, and Charcot-Marie-Tooth disease.

Helixmith clinical development and manufacturing activities are based in San Diego, California, where the company co-owns a cGMP-ready DNA production facility, Genopis, Inc., an affiliated CDMO also in San Diego. Genopis serves both Helixmith and external customers in need of plasmid DNA for medical purposes.

Share article on social media or email: